Cure Parkinson’s and Alzheimer’s Research UK announce a partnership
Cure Parkinson’s and Alzheimer’s Research UK are working on an initiative that could pave the way for innovative neurodegenerative treatments. There is a growing recognition that tackling neurodegenerative diseases could benefit from a collaborative, cross-disease approach. We are recognising the overlap in underlying biological...
Learn more
Alpha-synuclein or Tau in Parkinson’s?
The build-up of a protein called alpha-synuclein has been considered one of the hallmarks of Parkinson’s. Recently, however, a group of scientists have called into question the ‘bad guy’ role of alpha-synuclein.
Exploring Perspectives on Trial Design for Parkinson’s: An Update on the Delphi Study
Recently, Cure Parkinson’s was pleased to see the results of one of our funded studies published in the Journal of Parkinson’s Disease.
A review of our 2023 preclinical projects
In 2023, Cure Parkinson’s has funded five new preclinical projects. These preclinical projects address a wide range of ‘targets’ to understand which drugs and which targets should be further tested in a clinical trial.
A new potential biomarker for Parkinson’s
Researchers at Duke University have recently presented data on a new potential biomarker for Parkinson’s.
Our first pipeline project of research
Our first project from our Research Pipeline Acceleration Programme is now underway. Professor Michael Schwarzchild is investigating evidence needed to determine if three iLCT-evaluated compounds are ready to progress into clinical trials for people with Parkinson’s.